ReviewExpert reviews in molecular medicine2017
Helicobacter pylori as an oncogenic pathogen, revisited.
Review in Expert reviews in molecular medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 83 citations in OpenAlex.
- Beyond the Stomach: Exploring the Role ofExpert reviews in molecular medicine · 2026Review
- Allelic Variation ofMicroorganisms · 2025Article
- Helicobacter pylori Infection in Colombia: Phylogeny, Resistome, and Virulome.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2025Article
- The role of MAPK pathway in gastric cancer: unveiling molecular crosstalk and therapeutic prospects.Journal of translational medicine · 2024Review
- Review
- H. pylori infection and osteoporosis: a large-scale observational and mendelian randomization study.BMC infectious diseases · 2024Article
- Review
- Helicobacter pylori.Current topics in microbiology and immunology · 2024Review
- Pivotal role ofFrontiers in medicine · 2024Review
- Influence ofWorld journal of clinical oncology · 2022Review
- Characterization and Genomic Analysis of a New Phage InfectingInternational journal of molecular sciences · 2022Article
- The role of non-Helicobacter pylori bacteria in the pathogenesis of gastroduodenal diseases.Gut pathogens · 2022Review
- A comprehensive method for determining cellular uptake of purine nucleoside phosphorylase and adenylosuccinate synthetase inhibitors by H. pylori.Applied microbiology and biotechnology · 2021Article
- Impact of the Gut Microbiota Balance on the Health-Disease Relationship: The Importance of Consuming Probiotics and Prebiotics.Foods (Basel, Switzerland) · 2021Review
- Dietary Factors and Gastric Intestinal Metaplasia Risk Among US Veterans.Digestive diseases and sciences · 2021Observational
- Review
- Association of Dietary Cholesterol Intake With Risk of Gastric Cancer: A Systematic Review and Meta-Analysis of Observational Studies.Frontiers in nutrition · 2021Review
- Hippo-YAP signaling in digestive system tumors.American journal of cancer research · 2021Review
- Use of Acid-Suppressant Medications After Diagnosis Increases Mortality in a Subset of Gastrointestinal Cancer Patients.Digestive diseases and sciences · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Gastric cancer is an inflammation-associated malignancy aetiologically related to infection with the bacterium, Helicobacter pylori, which is considered a necessary but insufficient cause. Unless treated, H. pylori causes life-long acute and chronic gastric inflammation resulting in progressive gastric mucosal damage that may result in gastric cancer. The rate of progression from superficial gastritis, to an atrophic metaplastic mucosa, and ultimately to cancer relates to the virulence of the infecting H. pylori as well as host and environmental factors. H. pylori virulence is a reflection of its propensity to cause severe gastric inflammation. Both mucosal inflammation and H. pylori can cause host genomic instability, including dysregulation of DNA mismatch repair, stimulation of expression of activation-induced cytidine deaminase, abnormal DNA methylation and dysregulation of micro RNAs, which may result in an accumulation of mutations and loss of normal regulation of cell growth. The difference in cancer risk between the most and least virulent H. pylori strain is only approximately 2-fold. Overall, none of the putative virulence factors identified to date have proved to be disease-specific. The presence, severity, extent and duration of inflammation appear to be the most important factors and current evidence suggests that any host, environmental or bacterial factor that reliably enhances the inflammatory response to the H. pylori infection increases the risk of gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.